Effects of linagliptin on atherosclerotic progression in type 2 diabetics

Trial Profile

Effects of linagliptin on atherosclerotic progression in type 2 diabetics

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Linagliptin (Primary)
  • Indications Coronary artery disease; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 29 Jan 2014 New trial record
    • 20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top